-
Anacor Pharmaceuticals, Inc. v. Lupin Limited et al DC
- 1:18-cv-01606
- D. Del.
- Judge: Richard G. Andrews
- Filed: 10/17/2018
- Closed: 09/11/2020
- Latest Docket Entry: 09/27/2021
- PACER
- Docket updated daily
1
Plaintiff
5
Defendants
1
Accused
Product
4
Patents-in-Suit
696
Days in
Litigation
-
Anacor Pharmaceuticals, Inc. v. Lupin Limited et al DC
- 1:18-cv-01606
- D. Del.
- Judge: Richard G. Andrews
- Filed: 10/17/2018
- Closed: 09/11/2020
- Latest Docket Entry: 09/27/2021
- PACER
- Docket updated daily
Causes of Action
Infringement
Declaratory Judgment
Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Encube Ethicals Pvt. Ltd.
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,459,938 B1 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,566,289 B2 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,566,290 B2 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,572,823 B2 | All Asserted Claims |
No infringement
Entry 96
|
FlatWing Pharmaceuticals, LLC
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,459,938 B1 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,566,289 B2 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,566,290 B2 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,572,823 B2 | All Asserted Claims |
No infringement
Entry 96
|
Lupin Limited
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,459,938 B1 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,566,289 B2 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,566,290 B2 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,572,823 B2 | All Asserted Claims |
No infringement
Entry 96
|
Lupin Pharmaceuticals Incorporated
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,459,938 B1 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,566,289 B2 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,566,290 B2 | All Asserted Claims |
No infringement
Entry 96
|
| Generic Kerydin (TAVABOROLE) TOPICAL SOLUTION, 5% | US 9,572,823 B2 | All Asserted Claims |
No infringement
Entry 96
|
